Califf Lowering FDA Drawbridge To Work With External Expertise
This article was originally published in The Tan Sheet & The Rose Sheet
In Pink Sheet's exclusive interview, new commissioner says FDA will tap knowledge beyond its walls, without compromising agency independence.
You may also be interested in...
Former commissioner says agency has to think about getting biggest bang for the buck when considering a reorganization to disease-focused teams.
CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention.
FDA's concepts for new pathway could be ready for congressional scrutiny within a year.